中文摘要：

目的比较喹硫平与利培酮对儿童青少年早发性精神分裂症的临床疗效、安全性和耐受性。方法对61例发病年龄为10—18岁符合中国精神障碍分类与诊断标准第3版精神分裂症诊断标准的患者，采用喹硫平或利培酮治疗，其中喹硫平治疗者31例，利培酮治疗者30例。以临床疗效总评量表（CGI）、简明精神病评定量表（BPRS）评估有效性，采用副反应量表（TESS）和一些重要生理指标包括血压、体重等评估安全性和耐受性，观察期限为4周。结果喹硫平每日平均治疗剂量为（835±281）mg，平均加药时间为（8．35±5．89）d。利培酮每日平均治疗剂量为（5．83±1．13）mg，平均加药时间为（10．9±3．82）d。治疗4周后同组BPRS评分均明显低于治疗前，组间BPRS减分率差异无统计学意义（t=-0．157，P=0．876）；但喹硫平的锥体外系不良反应明显少于利培酮（χ^2=4．510，P=0．034）。结论本研究提示两种药物对治疗儿童青少年精神分裂症均有确切疗效，其中喹硫平的锥体外系不良反应更少。

英文摘要：

Objective： To compare the efficacy, security and tolerability of quetiapine and risperidone in the treatment of early onset schizophrenia. Methods： Sixty-one inpatients aged 10 -18 diagnosed with schizophrenia using CCMD -3 criteria were treated with quetiapine （31 cases）or risperidone （30 cases） for 4 weeks. Efficacy was assessed by using the clinical global impression （CGI） and the brief psychiatric rating scale （BPRS）. The security and tolerability were assessed by using the treatment emergent symptom scale （TESS）. Important physiological parameters including blood pressure and weight were also recorded. Results： The mean daily doses of quetiapine was （ 835 ± 281 ） mg and risperidone （5.83 ± 1.13 ） mg. The mean titration period of quetiapine was （ 8. 35 ± 5. 89 ） days and risperidone （ 10. 9 ±3. 82 ） days. BPRS scores were significantly decreased in both groups after 4 - week treatment, but there were no significant differences between them（t = - 0. 157, P = 0. 876）. However, the extrapyramidal reaction of＇quetiapine is fewer than that of risperidone （χ^2 = 4. 510, P = 0. 034）. Conclusion：The study suggests that the efficacy of quetiapine is as same as that of risperidone for early onset schizophrenia in children and adolescences, and the extrapyramidal reaction of quetiapine are fewer.